SCHEDULE 13G/A: Capitalink Ltd. Discloses 9.97% Stake in Clearmind Medicine
Beneficial Ownership Report (Amendment)
Capitalink Ltd. has filed an amended Schedule 13G, reporting a 9.97% beneficial ownership stake in Clearmind Medicine Inc., holding 5,980,397 common shares.
Summary
- Capitalink Ltd. beneficially owns 5,980,397 common shares of Clearmind Medicine Inc.
- This ownership represents 9.97% of Clearmind Medicine Inc.'s common shares outstanding.
- The percentage is calculated based on 59,991,852 common shares issued and outstanding as reported by Clearmind Medicine Inc. on December 3, 2025.
- Capitalink Ltd. holds sole voting power and sole dispositive power over all 5,980,397 shares.
- The filing is an Amendment No. 1 to a Schedule 13G.
- Capitalink Ltd. is an entity organized under the laws of Israel.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is purely informational.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from the issuer or the reporting person regarding future performance or strategic plans.
Management Comments
- Lavi Krasney, Chief Executive Officer of Capitalink Ltd., certified that the information set forth in the statement is true, complete, and correct to the best of his knowledge and belief.
Industry Context
This filing is a standard regulatory disclosure of a significant ownership stake by an institutional investor. It does not provide specific industry context or trends, but rather reflects an investment decision by Capitalink Ltd. in Clearmind Medicine Inc.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional holder (Capitalink Ltd.) with a 9.97% stake, which can influence market perception of the company's investor base.
Key Dates
| Date | Description |
|---|---|
| 12/03/2025 | Date of event which requires filing of this statement, and the date Clearmind Medicine Inc. reported 59,991,852 common shares outstanding. |
| 12/10/2025 | Date the Schedule 13G Amendment No. 1 was signed by Capitalink Ltd. |
Keywords
Clearmind Medicine Inc., Capitalink Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Equity Stake, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.